Kenvue Inc. $KVUE Stock Holdings Increased by Carmignac Gestion

Carmignac Gestion raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 166.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 420,432 shares of the company’s stock after buying an additional 262,858 shares during the quarter. Carmignac Gestion’s holdings in Kenvue were worth $8,034,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new position in Kenvue in the fourth quarter worth $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Kenvue during the second quarter worth $26,000. MV Capital Management Inc. acquired a new stake in shares of Kenvue during the fourth quarter worth $28,000. CoreCap Advisors LLC lifted its position in shares of Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Finally, Reflection Asset Management bought a new position in shares of Kenvue in the 4th quarter worth about $32,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE traded down $0.35 during mid-day trading on Tuesday, hitting $18.39. The stock had a trading volume of 16,219,959 shares, compared to its average volume of 27,713,732. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The company has a 50 day simple moving average of $19.18 and a 200-day simple moving average of $18.26. The stock has a market capitalization of $35.31 billion, a price-to-earnings ratio of 21.13, a P/E/G ratio of 1.67 and a beta of 0.46. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $20.13.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter last year, the company posted $0.29 EPS. Kenvue’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a $0.21 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.6%. Kenvue’s dividend payout ratio is currently 96.55%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KVUE. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group lowered their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Finally, Barclays increased their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.